Table 7.
ADME data of tested compounds calculated using preADMET software.
| Compound | Pharmacokinetics | |||||
|---|---|---|---|---|---|---|
| BBB a | Caco-2 b | HIA c | MDCK d | PPB e | CYP 2D6 f | |
| 6a | 0.041 | 22.28 | 100.00 | 16.84 | 90.09 | Non |
| 6b | 0.069 | 23.96 | 96.82 | 6.56 | 98.07 | Non |
| 6c | 0.075 | 23.23 | 97.44 | 6.31 | 94.65 | Non |
| 6d | 0.039 | 21.81 | 95.58 | 4.39 | 89.29 | Non |
| 6e | 0.039 | 21.79 | 95.58 | 4.39 | 89.41 | Non |
| 6f | 0.067 | 24.63 | 96.74 | 1.02 | 97.71 | Non |
| 6g | 0.05 | 21.85 | 96.01 | 8.51 | 84.71 | Non |
a BBB: blood–brain barrier penetration; b CACO-2: permeability through cells derived from human colon adenocarcinoma; c HIA: percentage human intestinal absorption; d MDCK: permeability through Madin–Darby canine kidney cells; e PPB: plasma protein binding; f CYP2D6: cytochrome P450 2D6.